compounded semaglutide fda enforcement 2025 news Drugmakers and pharmacists battle over who gets to make obesity drugs The FDA has received reports

The relationship between metabolically healthy obesity and the risk of cardiovascular disease: a systematic review and meta-analysis

Sarcinelli, C

You are taking levodopa : There is concern that taking SAM-e over a period of time may decrease the effectiveness of L-dopa, which is used for Parkinsons disease

Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets

The High-Priced Drug List is a market-based solution enabling competition from the country's 503A and 503B pharmacies when medications are priced higher in the United States compared to other developed countries

Semaglutide is perhaps the most well-known, marketed as Ozempic for diabetes and Wegovy for weight management